0
Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Á¶Ç÷¸ð¼¼Æ÷ ÀÌ½Ä »ýÁ¸ÀÚ¿Í È­Çпä¹ý »ýÁ¸ÀÚÀÇ »îÀÇ Áú¿¡ °üÇÑ ¿¬±¸

Quality of Life in Survivors of Patients after Hematopoietic Stem Cell Transplantation and Received Chemotherapy

ÀçÈ°°£È£ÇÐȸÁö 2003³â 6±Ç 2È£ p.127 ~ 136
KMID : 0939320030060020127
ÀÌÀº¿µ ( Lee Eun-Young ) - ºÎ»ê µ¿¾Æ´ëÇк´¿ø

¹ÚÇü¼÷ ( Park Hyoung-Sook ) - ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ °£È£Çаú
¼­Áö¹Î ( Seo Ji-Min ) - ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ °£È£Çаú

Abstract

Purpose: This study is to assess the quality of life(QOL) of hematic cancer survivors after hematopoietic stem cell transplantation(HSCT) and received chemotherapy(RC) to prepare basic information for nursing interventions in order to improve the patients¢¥ QOL.

Method: The data were collected by self-reporting questionnaire from January to March, 2003 intended for outpatients at the Cancer center of D university hospital in Busan. All 44 of them were diagnosed as hematic cancer and had spent 100 days after getting HSCT and complete remission(CR) throughout RC. The collected data were analyzed with descriptive statistics, t-test. ANOVA using SPSS/WIN 10.0 program.

Results: The total mean score of the QOL was moderate. In case of survivors in HSCT, the total mean score of the QOL was 5.81¡¾1.08, and that of survivors in RC was 5.94¡¾1.13. The facts above has not been considered statistically as the result of analysis of differences in each domain of the QOL depending on the general characteristics of the objects of this study.

Conclusion: The total mean score of the QOL was at moderate levels, indicating that the survivors after HSCT and RC were perceiving their QOL as moderate. In the nursing business aspect, the most important thing is to understand the QOL which the 2 groups of the survivors perceive, and the plans of nursing intervention that can be helpful to more qualitative life should be studied constantly.
KeyWords
Á¶Ç÷¸ð¼¼Æ÷À̽Ä, È­Çпä¹ý, »îÀÇ Áú
Hematopoietic stem cell transplantation, Chemotherapy, Quality of life
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed